JP2018504894A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504894A5
JP2018504894A5 JP2017532639A JP2017532639A JP2018504894A5 JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5 JP 2017532639 A JP2017532639 A JP 2017532639A JP 2017532639 A JP2017532639 A JP 2017532639A JP 2018504894 A5 JP2018504894 A5 JP 2018504894A5
Authority
JP
Japan
Prior art keywords
cell
car
antibody
nucleic acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067225 external-priority patent/WO2016100985A2/en
Publication of JP2018504894A publication Critical patent/JP2018504894A/ja
Publication of JP2018504894A5 publication Critical patent/JP2018504894A5/ja
Priority to JP2022011441A priority Critical patent/JP7548950B2/ja
Priority to JP2024147204A priority patent/JP7833003B2/ja
Pending legal-status Critical Current

Links

JP2017532639A 2014-12-19 2015-12-21 キメラ抗原受容体およびその使用方法 Pending JP2018504894A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022011441A JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法
JP2024147204A JP7833003B2 (ja) 2014-12-19 2024-08-29 キメラ抗原受容体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462094625P 2014-12-19 2014-12-19
US62/094,625 2014-12-19
US201562252083P 2015-11-06 2015-11-06
US62/252,083 2015-11-06
PCT/US2015/067225 WO2016100985A2 (en) 2014-12-19 2015-12-21 Chimeric antigen receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022011441A Division JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2018504894A JP2018504894A (ja) 2018-02-22
JP2018504894A5 true JP2018504894A5 (enExample) 2019-02-07

Family

ID=55229842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017532639A Pending JP2018504894A (ja) 2014-12-19 2015-12-21 キメラ抗原受容体およびその使用方法
JP2022011441A Active JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法
JP2024147204A Active JP7833003B2 (ja) 2014-12-19 2024-08-29 キメラ抗原受容体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022011441A Active JP7548950B2 (ja) 2014-12-19 2022-01-28 キメラ抗原受容体およびその使用方法
JP2024147204A Active JP7833003B2 (ja) 2014-12-19 2024-08-29 キメラ抗原受容体およびその使用方法

Country Status (11)

Country Link
US (3) US20170362297A1 (enExample)
EP (1) EP3233900A2 (enExample)
JP (3) JP2018504894A (enExample)
KR (2) KR102923234B1 (enExample)
CN (1) CN108064252A (enExample)
AU (4) AU2015364245B2 (enExample)
BR (1) BR112017013176A2 (enExample)
CA (1) CA2968412A1 (enExample)
IL (3) IL252295B2 (enExample)
RU (1) RU2017125531A (enExample)
WO (1) WO2016100985A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3134111B1 (en) * 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
US11549099B2 (en) * 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
SMT202600123T1 (it) 2016-06-29 2026-05-12 Checkpoint Therapeutics Inc Anticorpi specifici per il pd-l1 e metodi di utilizzo degli stessi
MX2019000149A (es) 2016-07-07 2019-09-23 Iovance Biotherapeutics Inc Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
WO2018057585A1 (en) * 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
AU2017338846B2 (en) * 2016-10-04 2020-09-24 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CN108148862B (zh) * 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
CN107337736B (zh) * 2017-06-06 2019-07-26 上海优卡迪生物医药科技有限公司 Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
WO2019178356A1 (en) * 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CA3097152A1 (en) * 2018-04-16 2019-10-24 Memorial Sloan Kettering Cancer Center T-cell exhaustion, & methods & compositions relating thereto
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
JP7262568B2 (ja) * 2018-07-24 2023-04-21 クレージュ メディカル カンパニー，リミテッド 免疫エフェクター細胞を使用して腫瘍を治療する方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
FI3856775T3 (fi) * 2018-09-27 2024-12-04 Autolus Ltd Kimeerinen antigeenireseptori
CA3120563A1 (en) * 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2019387566A1 (en) 2018-11-30 2021-06-17 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US11104732B2 (en) * 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15
US12479890B2 (en) * 2019-04-26 2025-11-25 The University Of North Carolina At Chapel Hill Chimeric antigen receptor constructs and their use in CAR-T cells
WO2020223445A1 (en) 2019-04-30 2020-11-05 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
WO2020252472A2 (en) 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
WO2021016606A1 (en) * 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Chimeric antigen receptor t cells and uses thereof
AU2020396896A1 (en) * 2019-12-02 2022-06-09 Dana-Farber Cancer Institute, Inc. Antibodies against PD-L1 and methods of use thereof
WO2021142835A1 (zh) * 2020-01-19 2021-07-22 北京卡替医疗技术有限公司 一种提升免疫细胞功能的增强受体
WO2021225399A1 (ko) * 2020-05-08 2021-11-11 (주)에스엠티바이오 암 치료를 위한 키메라 항원 수용체
AU2021320333A1 (en) 2020-08-07 2023-03-30 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
WO2022173950A1 (en) * 2021-02-11 2022-08-18 The Trustees Of The University Of Pennsylvania Ccr4-targeting chimeric antigen receptor cell therapy
KR20220136876A (ko) 2021-04-01 2022-10-11 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
TWI867291B (zh) * 2021-04-12 2024-12-21 中央研究院 經改良之冠狀病毒疫苗
KR20220144000A (ko) 2021-04-16 2022-10-26 주식회사 이뮤노로지컬디자이닝랩 Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
KR20230089464A (ko) 2021-12-13 2023-06-20 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20230089462A (ko) 2021-12-13 2023-06-20 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
CA3245511A1 (en) * 2022-03-08 2025-06-13 Vaxcell-Bio Co., Ltd. Pd-l1-specific chimeric antigen receptor and immune cell comprising same
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
CA2597717C (en) 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
BRPI0819971A2 (pt) 2007-12-06 2017-06-27 Burnham Institute For Medical Res anticorpos contra vírus influenza e métodos de seu uso
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2575882B1 (en) 2010-06-02 2017-11-01 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
ES3065694T3 (en) * 2012-04-11 2026-05-07 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
AU2013289971A1 (en) * 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Enhancing activity of CAR T cells by co-introducing a bispecific antibody
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
BR112015020516A2 (pt) * 2013-02-26 2017-10-10 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
SG11201507359SA (en) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
US20170174751A1 (en) 2014-03-19 2017-06-22 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
AU2015328273B2 (en) 2014-10-06 2020-09-17 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
RU2017125735A (ru) * 2014-12-19 2019-01-22 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы против карбоангидразы ix и способы их применения
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer

Similar Documents

Publication Publication Date Title
RU2017125531A (ru) Химерные антигенные рецепторы и способы их применения
WO2019090003A9 (en) Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
MX370788B (es) Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer.
JP2018500337A5 (enExample)
FI3560953T3 (fi) Solu
FI3896091T3 (fi) BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
HRP20191839T1 (hr) Car ekspresijski vektor i t stanice koje eksprimiraju car
JP2019527557A5 (enExample)
EP4424376A3 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
JP2016508518A5 (enExample)
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
HK1252235A1 (zh) 表达γ-δT细胞受体(TCR)和嵌合抗原受体(CAR)的T细胞
ZA201607060B (en) Drug related transgene expression
WO2017130223A3 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
JP2017529851A5 (enExample)
WO2017147383A8 (en) Modified cells for immunotherapy
JP2020533958A5 (enExample)
EP4477748A3 (en) Methods of making chimeric antigen receptor-expressing cells
CO2017006808A2 (es) Receptores de antígenos quiméricos de bcma
JP2014534207A5 (enExample)
WO2017066481A8 (en) Chimeric antigen receptors containing a chlorotoxin domain
JP2016514691A5 (enExample)
MX380109B (es) Metodo y composiciones para inmunoterapia celular.
JP2018514576A5 (enExample)
RU2017125735A (ru) Химерные антигенные рецепторы против карбоангидразы ix и способы их применения